[go: up one dir, main page]

HUP0003280A1 - Apolipoprotein A-1 agonista peptidek, ezeket hatóanyagként tartalmazó gyógyászati készítmények és alkalmazásuk - Google Patents

Apolipoprotein A-1 agonista peptidek, ezeket hatóanyagként tartalmazó gyógyászati készítmények és alkalmazásuk

Info

Publication number
HUP0003280A1
HUP0003280A1 HU0003280A HUP0003280A HUP0003280A1 HU P0003280 A1 HUP0003280 A1 HU P0003280A1 HU 0003280 A HU0003280 A HU 0003280A HU P0003280 A HUP0003280 A HU P0003280A HU P0003280 A1 HUP0003280 A1 HU P0003280A1
Authority
HU
Hungary
Prior art keywords
peptides
apolipoprotein
pharmaceutical compositions
agonist activity
diseases
Prior art date
Application number
HU0003280A
Other languages
English (en)
Inventor
Klaus Buttner
Isabelle Cornut
Jean-Louis Dasseux
Gunther Metz
Renate Sekul
Original Assignee
Klaus Buttner
Isabelle Cornut
Jean-Louis Dasseux
Gunther Metz
Renate Sekul
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klaus Buttner, Isabelle Cornut, Jean-Louis Dasseux, Gunther Metz, Renate Sekul filed Critical Klaus Buttner
Publication of HUP0003280A1 publication Critical patent/HUP0003280A1/hu
Publication of HUP0003280A3 publication Critical patent/HUP0003280A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

A találmány tárgyát a humán apolipoprotein A-I (ApoA-I) szerkezeti ésfarmakológiai tulajdonságait utánzó peptid vagy peptidanalóg-agonistapeptidek, ezeket tartalmazó gyógyáaszti készítmények képezik, amelyekalkalmasak a diszlipoproteinémiához kapcsolódó betegségek -beleértve ahiperkoleszterolémiát, a keringési betegségeket, az atheroszklerózist,a resztenózist, valamint más megbetegedéseket, mint például azaszeptikus sokkot - kezelésére. Apeptidek szerkezetére jellemző, hogy14-22 aminosav-maradékot tartalmaz, ami amfipatikus a-hélixet képezlipidek jelenlétében, vagy 1-8aminosavmaradék kivágásával a fenti 14-22tagú peptid vagy peptidanalóg deléciós formája. Ó
HU0003280A 1997-09-29 1998-09-28 Peptides having apolipoprotein a-1 agonist activity, pharmaceutical compositions comprising thereof and their use to treat dyslipidemic disorders HUP0003280A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/940,093 US6037323A (en) 1997-09-29 1997-09-29 Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders

Publications (2)

Publication Number Publication Date
HUP0003280A1 true HUP0003280A1 (hu) 2001-01-29
HUP0003280A3 HUP0003280A3 (en) 2005-06-28

Family

ID=25474213

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0003280A HUP0003280A3 (en) 1997-09-29 1998-09-28 Peptides having apolipoprotein a-1 agonist activity, pharmaceutical compositions comprising thereof and their use to treat dyslipidemic disorders

Country Status (19)

Country Link
US (5) US6037323A (hu)
EP (1) EP1019010B1 (hu)
JP (1) JP2003525840A (hu)
KR (1) KR100650974B1 (hu)
CN (1) CN1345245A (hu)
AT (1) ATE363287T1 (hu)
AU (1) AU747823B2 (hu)
CA (1) CA2304931A1 (hu)
DE (1) DE69837855T2 (hu)
ES (1) ES2288768T3 (hu)
HK (1) HK1044898A1 (hu)
HU (1) HUP0003280A3 (hu)
IL (1) IL135321A0 (hu)
NO (1) NO20001600L (hu)
NZ (1) NZ503719A (hu)
PL (1) PL200744B1 (hu)
RU (1) RU2219941C2 (hu)
UA (1) UA71554C2 (hu)
WO (1) WO1999016408A2 (hu)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046166A (en) * 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
DE60037818D1 (de) 1999-04-01 2008-03-06 Esperion Therapeutics Inc Ether-verbindungen, zusammensetzungen und ihre verwendung
AUPQ846900A0 (en) * 2000-06-29 2000-07-27 Aruba International Pty Ltd A vaccine
US7407662B2 (en) * 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified viral particles with immunogenic properties and reduced lipid content
US7407663B2 (en) * 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified immunodeficiency virus particles
US20090017069A1 (en) * 2000-06-29 2009-01-15 Lipid Sciences, Inc. SARS Vaccine Compositions and Methods of Making and Using Them
US7439052B2 (en) * 2000-06-29 2008-10-21 Lipid Sciences Method of making modified immunodeficiency virus particles
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
AU2007237157B2 (en) * 2000-08-24 2009-04-09 The Regents Of The University Of California Peptides that ameliorate atherosclerosis
US7166578B2 (en) * 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7144862B2 (en) * 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
DE10051983A1 (de) * 2000-10-20 2002-06-13 Beate Kehrel Inhibierung der pathogenen Wirkung oxidierter Proteine
ES2429528T3 (es) 2001-01-02 2013-11-15 The Cleveland Clinic Foundation Mieloperoxidasa, un indicador de riesgo para enfermedad cardiovascular
US20050089932A1 (en) * 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US7217785B2 (en) * 2001-05-09 2007-05-15 The Regents Of The University Of California Cysteine-containing peptides having antioxidant properties
US20030127386A1 (en) * 2001-06-25 2003-07-10 Bomberger David C. Hollow fiber contactor systems for removal of lipids from fluids
US6991727B2 (en) * 2001-06-25 2006-01-31 Lipid Sciences, Inc. Hollow fiber contactor systems for removal of lipids from fluids
EP1412045A4 (en) * 2001-06-25 2007-05-02 Lipid Sciences Inc A SOLVENT FOR REMOVING LIPIDES FROM FLUIDS USING SYSTEMS AND METHOD
US20060060520A1 (en) * 2001-06-25 2006-03-23 Bomberger David C Systems and methods using a solvent for the removal of lipids from fluids
WO2003000381A1 (en) * 2001-06-25 2003-01-03 Lipid Sciences, Inc. Hollow fiber contactor systems for removal of lipids from fluids
CN1635873A (zh) * 2001-09-28 2005-07-06 埃斯佩里安医疗公司 在高压下挤出泡囊的方法和装置
WO2003026492A2 (en) * 2001-09-28 2003-04-03 Esperion Therapeutics Inc. Prevention and treatment of restenosis by local administration of drug
US20040009216A1 (en) * 2002-04-05 2004-01-15 Rodrigueza Wendi V. Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
US20100204103A1 (en) * 2002-05-08 2010-08-12 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
US20040067873A1 (en) * 2002-05-17 2004-04-08 Dasseux Jean-Louis H. Method of treating dyslipidemic disorders
MXPA04011227A (es) * 2002-05-17 2005-01-25 Esperion Therapeutics Inc Metodos y composiciones para el tratamiento de la reperfusion isquemica.
US6953840B2 (en) * 2002-07-30 2005-10-11 Esperion Therapeutics, Inc. Methods of using non-human animal Apolipoprotein A-I protein
JP2005538148A (ja) * 2002-08-26 2005-12-15 リピド サイエンスィズ インコーポレイテッド 脱脂タンパク質粒子を使用したアルツハイマー病治療
EP2402300B1 (en) * 2003-01-23 2016-05-25 Esperion Therapeutics Inc. Hydroxyl compounds and compositions for cholesterol management and related uses
CA2522758A1 (en) * 2003-04-22 2004-11-04 Avanir Pharmaceuticals Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
US7393826B2 (en) * 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
WO2005011620A2 (en) * 2003-07-03 2005-02-10 Lipid Sciences Inc. Methods and apparatus for creating particle derivatives of hdl with reduced lipid content
US7459286B1 (en) * 2003-10-22 2008-12-02 The Cleveland Clinic Foundation Assessing the risk of a major adverse cardiac event in patients with chest pain
US6960803B2 (en) * 2003-10-23 2005-11-01 Silicon Storage Technology, Inc. Landing pad for use as a contact to a conductive spacer
AU2004296829A1 (en) 2003-12-05 2005-06-23 The Cleveland Clinic Foundation Risk markers for cardiovascular disease
WO2005058938A2 (en) * 2003-12-15 2005-06-30 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
EP1699527A1 (en) 2004-01-02 2006-09-13 Advanced Cardiovascular Systems, Inc. High-density lipoprotein coated medical devices
EP1732383A4 (en) * 2004-04-06 2007-05-02 Cedars Sinai Medical Center PREVENTION AND TREATMENT OF VASCULAR DISEASES WITH RECOMBINANT ADENO ASSOCIATED VIRUS VECTORS THAT CODE APOLIPOPROTEIN A-I AND APOLIPOPROTEIN A-I MILANO
US7378396B2 (en) * 2004-08-11 2008-05-27 The Cleveland Clinic Foundation Therapeutic agents and methods for cardiovascular disease
US20060205669A1 (en) * 2004-09-16 2006-09-14 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
WO2006049597A1 (en) * 2004-10-27 2006-05-11 Avanir Pharmaceuticals Amino acid-derived compounds as modulators of the reverse cholesterol transport
NZ555826A (en) 2004-12-06 2009-11-27 Univ California Methods for improving the structure and function of arterioles
US20060160721A1 (en) * 2004-12-22 2006-07-20 Baylor College Of Medicine Method of plasma lipidation to prevent, inhibit and/or reverse atherosclerosis
US7759315B2 (en) 2005-03-09 2010-07-20 Csl Behring Ag Treatment of inflammatory conditions of the intestine
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
BRPI0610983A2 (pt) 2005-04-29 2010-08-10 Universirty Of California peptìdeos e miméticos de peptìdeos para tratar patologias caracterizadas por uma resposta inflamatória
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
KR101577554B1 (ko) 2005-08-22 2015-12-14 멜리어 파마슈티칼스 아이, 인코포레이티드 Ｌｙｎ 키나제 활성의 조절 및 관련된 장애의 치료를 위한 방법 및 제제
US20070254832A1 (en) * 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
WO2007137400A1 (en) * 2006-06-01 2007-12-06 Institut De Cardiologie De Montreal Method and compound for the treatment of valvular stenosis
US20080206142A1 (en) * 2006-06-16 2008-08-28 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
US20080227686A1 (en) * 2006-06-16 2008-09-18 Lipid Sciences, Inc. Novel Peptides that Promote Lipid Efflux
WO2007149355A2 (en) * 2006-06-16 2007-12-27 Lipid Sciences, Inc. Novel peptides that promote lipid efflux
WO2008021088A2 (en) 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
US20080138284A1 (en) * 2006-09-26 2008-06-12 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
US8541236B2 (en) * 2006-12-08 2013-09-24 University Of Washington Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls
WO2008094905A2 (en) * 2007-01-29 2008-08-07 Lipid Sciences, Inc. Encapsulated hdl mimetic peptides
CA2676977C (en) * 2007-01-31 2016-10-04 Nutrition 21, Inc. Use of chromium histidinate for treatment of cardiometabolic disorders
KR20100014480A (ko) * 2007-02-20 2010-02-10 멜리어 파마슈티칼스 아이, 인코포레이티드 Ｌｙｎ 키나제 활성제의 확인 방법
ATE555801T1 (de) 2007-03-01 2012-05-15 Csl Ltd Behandlung von endothelialer dysfunktion bei diabetes-patienten
PL3050568T3 (pl) 2007-03-13 2021-06-14 Jds Therapeutics, Llc Sposoby i kompozycje do przedłużonego uwalniania chromu
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
NZ579288A (en) * 2007-07-23 2012-06-29 Melior Discovery Inc Methods of activating irs-1 and akt
US9422363B2 (en) 2007-08-28 2016-08-23 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
WO2009032702A2 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
US8044021B2 (en) 2007-09-20 2011-10-25 Abbott Cardiovascular Systems Inc. Sustained release of apo A-I mimetic peptides and methods of treatment
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
US8101565B2 (en) 2007-09-20 2012-01-24 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US9173890B2 (en) 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8552184B2 (en) * 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
US8241861B1 (en) 2008-07-08 2012-08-14 Insilicos, Llc Methods and compositions for diagnosis or prognosis of cardiovascular disease
CN111909020A (zh) 2008-11-10 2020-11-10 阿布特斯生物制药公司 用于递送治疗剂的脂质和组合物
US20120101148A1 (en) 2009-01-29 2012-04-26 Alnylam Pharmaceuticals, Inc. lipid formulation
PL2396017T3 (pl) 2009-02-16 2015-12-31 Cerenis Therapeutics Holding Sa Mimetyki apolipoproteiny A-l
CA2754043A1 (en) 2009-03-12 2010-09-16 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
KR20240015723A (ko) 2009-05-05 2024-02-05 알닐람 파마슈티칼스 인코포레이티드 지질 조성물
CA2764609C (en) 2009-06-10 2018-10-02 Alnylam Pharmaceuticals, Inc. Improved cationic lipid of formula i
WO2011020023A2 (en) 2009-08-14 2011-02-17 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
US20120270771A1 (en) * 2009-09-30 2012-10-25 Snu R&Db Foundation Apolipoprotein a-1 mimic peptides, and therapeutic agent for treating hyperlipidemia and diseases related to hyperlipidemia comprising same
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
WO2011044545A2 (en) 2009-10-09 2011-04-14 Sigalov Alexander B Methods and compositions for targeted imaging
AU2010328336B2 (en) 2009-12-07 2017-03-02 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
WO2011075656A1 (en) 2009-12-18 2011-06-23 The University Of British Columbia Methods and compositions for delivery of nucleic acids
US20130156845A1 (en) 2010-04-29 2013-06-20 Alnylam Pharmaceuticals, Inc. Lipid formulated single stranded rna
WO2011143362A1 (en) 2010-05-11 2011-11-17 Esperion Therapeutics, Inc. Dimeric oxidation-resistant apolipoprotein a1 variants
WO2011150300A1 (en) 2010-05-28 2011-12-01 Melior Pharmaceuticals I, Inc. Prevention of pancreatic beta cell degeneration
ES3053320T3 (en) 2010-06-03 2026-01-21 Alnylam Pharmaceuticals Inc Biodegradable lipids for the delivery of active agents
WO2012016188A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
EP2611419A2 (en) 2010-08-30 2013-07-10 F.Hoffmann-La Roche Ag Method for producing a tetranectin-apolipoprotein a-1 lipid particle, the lipid particle itself and its use
US9339513B2 (en) 2010-11-09 2016-05-17 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
EP3202760B1 (en) 2011-01-11 2019-08-21 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
CN103443123B (zh) 2011-02-07 2020-05-29 塞勒尼斯医疗控股公司 脂蛋白复合物及其制备和用途
AU2012223282B2 (en) 2011-03-01 2017-02-02 Nutrition 21, Llc Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
JP6250543B2 (ja) 2011-09-27 2017-12-20 アルニラム・ファーマシューティカルズ・インコーポレーテッド ジ脂肪族置換ｐｅｇ化脂質
WO2013090319A2 (en) 2011-12-12 2013-06-20 Melior Pharmaceuticals I, Inc. Treatment of type i and type ii diabetes
CN103073646A (zh) * 2012-03-13 2013-05-01 华中科技大学 一种运载蜂毒肽的多肽、运载蜂毒肽的纳米颗粒及其应用
EP2983687B1 (en) 2013-03-15 2019-09-04 The Regents of The University of California Peptides having reduced toxicity that stimulate cholesterol efflux
EP2853259A1 (en) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
MX2016014306A (es) 2014-05-02 2017-06-12 Cerenis Therapeutics Holding Sa Marcadores para terapia con lipoproteinas de alta densidad (hdl).
US10220046B2 (en) 2014-07-14 2019-03-05 The Regents Of The University Of Michigan Compositions and methods for disease treatment using nanoparticle delivered compounds
USRE50320E1 (en) 2014-07-31 2025-03-04 Uab Research Foundation APOE mimetic peptides and higher potency to clear plasma cholesterol
US10307491B2 (en) 2015-01-30 2019-06-04 The Regents Of The University Of Michigan Liposomal particles comprising biological molecules and uses thereof
US10912751B2 (en) 2015-03-13 2021-02-09 Esperion Therapeutics, Inc. Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
EP3273944B1 (en) 2015-03-25 2024-11-20 The Regents of The University of Michigan Compositions and methods for delivery of biomacromolecule agents
MX2018009748A (es) 2016-02-11 2019-02-07 Nutrition 21 Llc Composiciones que contienen cromo para mejorar la salud y el estado físico.
US12257352B2 (en) 2016-06-20 2025-03-25 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
US10821133B2 (en) 2017-12-28 2020-11-03 Hdl Therapeutics, Inc. Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma
AU2018250795B2 (en) 2017-04-10 2022-02-10 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Treatment of adipocytes
EP3668600B1 (en) 2017-08-10 2024-05-15 Abionyx Pharma SA Cargomers
CN111868232B (zh) 2017-11-22 2024-05-28 Hdl治疗公司 用于对血浆处理系统的流体回路进行灌注的系统和方法
JP2022537049A (ja) 2019-06-21 2022-08-23 エスペリオン・セラピューティクス・インコーポレイテッド ベンペド酸の製造方法及びその組成物
JP2023522889A (ja) 2020-04-16 2023-06-01 アビオニクス ファーマ エスエー 脂質結合タンパク質ベースの複合体を使用した、急性病態を治療するための方法
JP2023543498A (ja) 2020-10-01 2023-10-16 アビオニクス ファーマ エスエー 脂質結合タンパク質ベースの複合体を使用した、眼疾患を治療するための方法
US20220117513A1 (en) * 2020-10-16 2022-04-21 Cedars-Sinai Medical Center Microbiome-derived gaseous sample collection system and methods
CN117479834A (zh) 2021-04-15 2024-01-30 阿比奥尼克斯制药公司 基于脂质结合蛋白的复合物在器官保存溶液中的用途
WO2023194798A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
IL316110A (en) 2022-04-06 2024-12-01 Abionyx Pharma Sa Methods for treating eye diseases using complexes based on fat-binding protein
CA3258787A1 (en) 2022-06-10 2023-12-14 Stanislas FAGUER METHODS OF TREATMENT OF HYPERINFLAMMATORY DISEASES USING LIPID-BINDING PROTEIN COMPLEXES
EP4536269A2 (en) 2022-06-10 2025-04-16 Abionyx Pharma SA Methods for treating acute conditions using lipid binding protein-based complexes
IL322074A (en) 2023-01-13 2025-09-01 Abionyx Pharma Sa Treatment using a lipid-binding protein molecule
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621479A5 (hu) * 1977-08-05 1981-02-13 Battelle Memorial Institute
CA1173360A (en) * 1979-06-22 1984-08-28 Jurg Schrank Pharmaceutical preparations
DE3241102A1 (de) * 1982-11-06 1984-05-10 A. Nattermann & Cie GmbH, 5000 Köln Imidazolylalkylthienyl-tetrahydropyridazine und verfahren zu ihrer herstellung
US4643988A (en) * 1984-05-15 1987-02-17 Research Corporation Amphipathic peptides
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US4857319A (en) * 1985-01-11 1989-08-15 The Regents Of The University Of California Method for preserving liposomes
US5204328A (en) * 1990-06-26 1993-04-20 Merck & Co., Inc. Peptides having atrial natriuretic factor activity
DK53291D0 (da) * 1991-03-25 1991-03-25 Carlbiotech Ltd As Smaa peptider og peptidrelaterede stoffer samt farmaceutiske praeparater indeholdende saadanne forbindelser
US5527790A (en) * 1991-09-30 1996-06-18 The University Of British Columbia Bis(maltolato)oxovanadium compositions for the treatment of elevated blood sugar
US5578287A (en) * 1992-06-09 1996-11-26 Neorx Corporation Three-step pretargeting methods using improved biotin-active agent
JPH07507554A (ja) * 1992-06-12 1995-08-24 エヌ・ブイ・イノゲネテイクス・エス・エイ 新規ペプチドおよびタンパク質，それらの調製方法，ならびにコレステロール受容体としてのそれらの使用
US5674855A (en) * 1992-08-12 1997-10-07 The Rogosin Institute Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions
US5470753A (en) * 1992-09-03 1995-11-28 Selectide Corporation Peptide sequencing using mass spectrometry
SE9203753D0 (sv) * 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
FR2723741A1 (fr) * 1994-08-16 1996-02-23 Fournier Sca Lab Peptides inhibiteurs de la proteine de transfert des esters de cholesterol et leur utilisation en therapeutique
US5545661A (en) * 1995-05-16 1996-08-13 Eli Lilly And Company Methods for inhibiting bone loss with bis-pyrone oxovanadium compounds
FR2734568B1 (fr) * 1995-05-22 1997-06-20 Rhone Poulenc Rorer Sa Nouveaux variants de l'apolipoproteine
NZ331980A (en) * 1996-03-29 2000-09-29 Helmut Hauser Amphipathic peptides with alpha helices as cholesterol and other lipid uptake inhibitors
RU2101287C1 (ru) * 1996-04-16 1998-01-10 Научно-исследовательский институт биомедицинской химии РАМН Оксованадиевые комплексы l-яблочной кислоты, проявляющие гипогликемическую активность
GB9609702D0 (en) * 1996-05-09 1996-07-10 Royal Free Hosp School Med Anticoagulant peptides
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders

Also Published As

Publication number Publication date
AU747823B2 (en) 2002-05-23
HUP0003280A3 (en) 2005-06-28
HK1044898A1 (zh) 2002-11-08
ES2288768T3 (es) 2008-01-16
KR100650974B1 (ko) 2006-11-29
US20080058270A1 (en) 2008-03-06
KR20010030805A (ko) 2001-04-16
AU9779198A (en) 1999-04-23
EP1019010B1 (en) 2007-05-30
NO20001600L (no) 2000-05-03
EP1019010A1 (en) 2000-07-19
US20030008827A1 (en) 2003-01-09
US20040029807A9 (en) 2004-02-12
NO20001600D0 (no) 2000-03-28
ATE363287T1 (de) 2007-06-15
PL362598A1 (en) 2004-11-02
NZ503719A (en) 2002-09-27
US6734169B2 (en) 2004-05-11
CA2304931A1 (en) 1999-04-08
US6037323A (en) 2000-03-14
CN1345245A (zh) 2002-04-17
US7211565B2 (en) 2007-05-01
IL135321A0 (en) 2001-05-20
WO1999016408A2 (en) 1999-04-08
DE69837855T2 (de) 2008-02-07
PL200744B1 (pl) 2009-01-30
RU2219941C2 (ru) 2003-12-27
UA71554C2 (en) 2004-12-15
US6265377B1 (en) 2001-07-24
DE69837855D1 (de) 2007-07-12
US20040198662A1 (en) 2004-10-07
EP1019010A4 (en) 2003-07-23
JP2003525840A (ja) 2003-09-02

Similar Documents

Publication Publication Date Title
HUP0003280A1 (hu) Apolipoprotein A-1 agonista peptidek, ezeket hatóanyagként tartalmazó gyógyászati készítmények és alkalmazásuk
HUP0103114A2 (hu) Apolipoprotein A-1 agonisták és alkalmazásuk diszlipidémiás rendellenességek kezelésében
ATE383865T1 (de) Apolipoprotein a-i agonisten und deren verwendung zur behandlung dyslipidämischer erkrankungen
HUP0004560A2 (hu) Törést gyógyító PTHrP analógok
DK0535091T3 (da) Knogleinducerende farmaceutiske formuleringer
RU2000111526A (ru) Генотерапевтические способы введения агонистов аполипопротеина а-i и их применение для лечения дислипидемических нарушений
YU5396A (sh) Novi biološki aktivni proteini, njihove farmaceutske formulacije i postupak za njihovo dobijanje
YU71395A (sh) Acilovani analozi insulina
HUP0003924A2 (hu) Génterápiás megközelítések ApoA-I agonisták biztosítására, valamint ezek alkalmazása diszlipidémiás rendellenességek kezelésében
ATE169304T1 (de) Biologisch aktive peptide aus funktionellen domaenen des bakteriziden/ die permeabilitaet erhoehenden proteins und ihre verwendung
ATE198050T1 (de) Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
BG104266A (en) Aminoterminally incised mcp-2 as haemokin antagonists
NL300830I1 (nl) Protein Q, een recombinant chimeer eiwit, bestaande uit vijf antigenefragmenten van vier verschillende Leishmania infantum (zymodeme Mon-1) eiwitten
ATE359296T1 (de) Pharmazeutische peptide formulierungen zur behandlung von staubmilben allergie
WO1991003226A3 (en) Pharmaceutical compositions containing aromatic polymers and therapeutic methods using the same
Garcia Denegri et al. Venoms and isolated toxins from snakes of medical impact in the north-east Argentina: state of the art. Potential pharmacological applications
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
DE69420574D1 (de) Derivate von therapeutisch in der blutgerinnungskaskade wirksamen peptiden, verfahren zur herstellung und sie enthaltende pharmazeutische zubereitungen
ES2119746T3 (es) Nuevo peptido fisiologicamente activo y agente regulador del metabolismo del calcio que comprende dicho peptido como ingrediente activo.
AU7435298A (en) Compositions for enhancing immunosuppressants' pharmaceutical acti vities

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees